Vaccination against canine rabies is the most effective prophylactic measure to prevent cases of human rabies. In Brazil, domestic animal vaccination campaign is carried out based on annual boosters due to particular vaccine characteristics to consider an animal immunized. The vaccines used today are from inactivated virus plus adjuvant. Protection is considered by a level of high antibody, because effective immune response to rabies virus depends on their rapid neutralization before its spread. Although rabies vaccines are available and free, there is an important fault coverage due to the need of constant boosters, which leads many owners to stop vaccinating their pets. Having this in mind, the development of new vaccines against rabies should aim increase the interval between booster doses, or even facilitating the administration process. The purpose of this research is to develop a prototype vaccine based on the use of a recombinant glycoprotein from rabies virus envelope. This glycoprotein expressed in S2 cells in an extensively characterized system, has demonstrated immunogenic properties in preliminary tests. We intend to use this antigen combined with different adjuvants and the use of different routes of immunization in animal model, verifying levels of protection. Obtaining a new formulation for the prevention of canine rabies may generate an innovative new vaccine, especially if it is effective is could be proven orally.
News published in Agência FAPESP Newsletter about the scholarship: